drugset / Trial / NCT01144949

Study of Silodosin to Facilitate Passage of Urinary Stones

NCT01144949

Phase 2 Completed 239 enrolled Watson Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.

Timeline

Start
2010-06
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Silodosin Unknown 8 mg Oral